ARC 13950
Alternative Names: FPL 13950Latest Information Update: 18 Jan 2007
At a glance
- Originator AstraZeneca R&D Charnwood
- Class Acetamides; Antiepileptic drugs; Neuroprotectants
- Mechanism of Action Glutamate receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed
- 28 Jan 1999 FPL 13590 is now called ARC 13590
- 18 Aug 1995 Preclinical development for Epilepsy in USA (unspecified route)